• LAST PRICE
    0.7001
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.7000/ 7
  • Ask / Lots
    0.7800/ 26
  • Open / Previous Close
    0.0000 / 0.7001
  • Day Range
    ---
  • 52 Week Range
    Low 0.6100
    High 7.8000
  • Volume
    459
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.6221
TimeVolumeTCRT
09:32 ET3240.6221
09:38 ET30820.6542
09:43 ET10260.63
09:45 ET8130.63
10:08 ET10330.63
10:12 ET2000.6301
10:14 ET1000.768
10:15 ET1000.664
10:55 ET3500.68
10:57 ET2110.7185
11:13 ET41970.7
11:15 ET5210.719
11:22 ET1000.736
11:24 ET8500.7001
11:26 ET2110.7091
11:27 ET23920.7001
11:29 ET52870.72
11:31 ET40000.74
11:33 ET5000.739999
11:44 ET1500.719999
11:49 ET1000.719999
11:51 ET5330.720001
11:58 ET2470.7
12:05 ET27770.74
12:50 ET11800.7201
01:06 ET34340.72
01:08 ET2000.72
01:15 ET1000.72
01:19 ET32960.7023
01:37 ET4500.7023
01:46 ET2990.7004
01:48 ET5900.72
01:50 ET5770.7004
01:53 ET2000.7399
02:15 ET2000.717001
02:24 ET5720.7
02:33 ET1000.700001
02:56 ET1500.705915
03:21 ET8000.7085
03:41 ET4780.7
03:43 ET30000.7
03:45 ET32500.7
03:52 ET2500.7
03:56 ET14270.70005
03:57 ET13190.7001
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTCRT
Alaunos Therapeutics Inc
11.2M
-0.4x
---
United StatesADXS
Ayala Pharmaceuticals Inc
11.2M
0.0x
---
United StatesKPRX
Kiora Pharmaceuticals Inc
11.1M
-0.3x
---
United StatesATHE
Alterity Therapeutics Ltd
17.5M
-0.9x
---
United StatesMIRA
Mira Pharmaceuticals Inc
10.6M
-0.9x
---
United StatesENZN
Enzon Pharmaceuticals Inc
11.9M
53.7x
-60.21%
As of 2024-06-24

Company Information

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.

Contact Information

Headquarters
2617 Bissonnet St, Suite 225HOUSTON, TX, United States 77005
Phone
617-259-1970
Fax
617-241-2855

Executives

Independent Chairman of the Board
Holger Weis
Interim Chief Executive Officer, Director
Dale Hogue
Vice President - Finance
Ferdinand Groenewald
Independent Director
Robert Hofmeister
Independent Director
Robert Postma

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$11.2M
Revenue (TTM)
$6.0K
Shares Outstanding
16.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.49
EPS
$-1.67
Book Value
$0.39
P/E Ratio
-0.4x
Price/Sales (TTM)
1,868.4
Price/Cash Flow (TTM)
---
Operating Margin
-438,950.00%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.